Back to Academy

What Is a Phase 4 Clinical Trial? (And What It Means for MedTech)

In a Phase 4 clinical trial, researchers study a drug or treatment after it has been approved and made available to the public. Phase 4 begins once a product has moved from the pre-market to the post-market stage, and it continues for as long as the product is in use.

To see how post-market studies fit with the earlier exploratory and confirmatory phases, read our complete guide to the phases of clinical trials.

In the pharmaceutical industry, Phase 4 focuses on the safety, risks, benefits and best use of a drug or treatment in everyday practice. Medical device manufacturers have an equivalent obligation to keep collecting clinical data once their products are on the market. This guide also covers the corresponding post-market clinical follow-up (PMCF) and surveillance pathways for MedTech.

In short

  • Definition: A Phase 4 clinical trial (also called a Phase 4 study or post-marketing surveillance trial) is a clinical study conducted after a drug or treatment has received regulatory approval and is available on the market.
  • Primary objective: To evaluate real-world effectiveness, long-term safety, rare adverse events and optimal use in broader, more diverse patient populations over extended periods.
  • MedTech equivalent: In medical devices, the equivalent of Phase 4 is post-market clinical follow-up (PMCF). For in vitro diagnostics (IVD), it is post-market performance follow-up (PMPF). Both sit within the manufacturer's wider post-market surveillance (PMS) system and are often run through clinical registries.
  • Who is Ledidi? Ledidi is a Norwegian software company founded by academic surgeons and software engineers. Ledidi enables MedTech companies to manage clinical evidence in-house, from early feasibility and trials through to PMCF and multi-site registries, all on one secure and affordable platform. Our unified cloud platform, comprising Ledidi Core, Ledidi Trials and Ledidi Registries, combines data capture, real-time analytics and global collaboration.

What is a Phase 4 clinical trial? Definition and core purpose

A Phase 4 clinical trial is a study of a drug or treatment that has already been approved and is on the market. Its purpose is to build on the evidence from Phases 1 to 3 by studying the product in routine clinical practice, over longer periods and in larger, more varied patient populations.

Phase 4 studies can be voluntary or required by regulators as a condition of approval:

  • EU: The European Medicines Agency (EMA) and national authorities can require Post-Authorisation Safety Studies (PASS) and Post-Authorisation Efficacy Studies (PAES).
  • US: The Food and Drug Administration (FDA) can require postmarketing studies, known as postmarketing requirements. Sponsors can also agree to studies voluntarily, known as postmarketing commitments.

Phase 4 studies run alongside pharmacovigilance, the ongoing collection and assessment of adverse event reports. Together, they form the evidence base that keeps a product's benefit-risk balance under review throughout its life on the market.

Why Phase 4 matters: from controlled trials to real-world use

Once a product moves from pre-market investigation (Phases 1 to 3) to post-authorisation use, it is tested in the real world. In Phases 1 to 3, research takes place in a tightly controlled environment with strict inclusion and exclusion criteria. A pre-market Phase 3 trial might, for example, exclude elderly patients or pregnant individuals. Other medicines that participants take at the same time are tightly restricted, and participants are expected to follow strict dosing schedules.

Once a drug or medical device is launched commercially, it enters clinical reality. Patients may miss doses or take unmonitored over-the-counter supplements, and they are no longer monitored as often as during scheduled study visits. Real-world cohorts also include broader demographic groups that were underrepresented in pre-approval trials.

In Phase 4, researchers keep tracking the safety and effectiveness of the product or device. Valuable insights build up over time, both on factors evaluated in Phases 1 to 3 and on factors that may have been overlooked, such as age groups, ethnic backgrounds or comorbidities. Phase 4 studies therefore bridge the gap between efficacy (how well a product works under ideal trial conditions) and effectiveness (how well it works in everyday practice).

Key objectives of a Phase 4 study

  • Detecting rare adverse drug reactions (ADRs): Pre-market trials involve a few thousand patients at most, so reactions that affect only one in several thousand people are often not seen until the drug is used much more widely.
  • Assessing long-term efficacy and safety: Phase 4 studies often follow patients for several years, and ongoing surveillance can continue for decades. This reveals effects that only appear after long-term use.
  • Comparing real-world effectiveness with trial efficacy: Researchers assess what changes when patients manage their own treatment, take other medicines alongside it, or have conditions that would have excluded them from earlier trials.
  • Exploring health economics and quality of life (QoL): Health technology assessment (HTA) and reimbursement bodies, such as the National Institute for Health and Care Excellence (NICE) in the UK, rely on these metrics to judge whether a treatment offers value for money. Phase 4 and post-market observational studies collect patient-reported outcome measures (PROMs), hospitalisation rates, incremental cost-effectiveness ratios (ICER) and quality-adjusted life years (QALYs) to support continued public or private payer coverage.
  • Studying new populations and interactions: Phase 4 studies can explore how a product performs in groups that were underrepresented in earlier trials, such as older adults, children or patients with multiple conditions, and how it interacts with other medicines.

Types of Phase 4 study designs

  • Post-authorisation safety studies (PASS): Studies designed to investigate a specific safety concern. Most are non-interventional, but some are interventional clinical trials.
  • Non-interventional and observational studies: Prospective or retrospective studies where treatment follows standard clinical practice, including cohort studies and analyses of existing healthcare databases.
  • Patient and disease registries: Longitudinal databases collecting structured real-world data (RWD) over years.
  • Pragmatic clinical trials (PCTs): Randomised trials run within everyday clinical practice, often comparing the approved product with other available treatments.

Delve further into clinical trial design: read our 2026 guide to best practices.

How Phase 4 compares with Phase 3

Phase 4 clinical trials are post-market. They focus on long-term safety, rare side effects and real-world effectiveness in broad patient populations. Phase 3, by contrast, is the final pre-market phase, focused on proving efficacy to secure regulatory approval.

AspectPhase 3Phase 4
StageFinal pre-market phasePost-market, after approval
SettingControlled, with strict inclusion and exclusion criteriaRoutine clinical practice
PopulationTypically 1,000 to 3,000 selected patientsBroad, diverse general patient population
Main questionDoes it work, and is it safe enough to approve?How does it perform in the real world over time?
Duration1 to 4 yearsSeveral years, often for as long as the product is on the market

Phase 4 in MedTech: how post-market trials look for medical devices and IVDs

If you are a MedTech or diagnostics team, you will not run a Phase 4 trial in the pharma sense. The equivalent stage is post-market clinical follow-up (PMCF) for medical devices, or post-market performance follow-up (PMPF) for IVDs. Both start once the product is on the market and continue for its entire commercial lifetime.

Like Phase 4 in pharma, the objective is to track long-term performance, reliability and rare adverse events. Devices also raise different long-term questions from drugs. Implants can wear, loosen or interact with surrounding tissue over many years. Performance can depend on the user's technique and experience, and design changes after launch can affect safety. Identifying these issues is critical to improving device design and ensuring ongoing safe, effective use.

The MedTech equivalents

Each type of medical product has its own post-market evidence requirements.

Medical devices: PMCF and PMS

Under the European Medical Device Regulation (MDR), post-market oversight is split between two different but complementary mechanisms:

  • Post-market clinical follow-up (PMCF): Covered by Annex XIV (Part B) of the EU MDR, PMCF is a proactive process for collecting clinical data to verify safety, performance and the benefit-risk ratio. PMCF activities can be general, such as literature reviews and structured user feedback, or specific, such as PMCF studies, clinical registries and patient surveys. Under the MDR, PMCF must always be considered, and if a manufacturer decides it is not needed, that decision must be justified.
  • Post-market surveillance (PMS): The manufacturer's overall system for monitoring a device once it is on the market, set out in Articles 83 to 86 of the MDR. It covers complaints, vigilance reporting of serious incidents, trend analysis, and either a Periodic Safety Update Report (PSUR) or, for Class I devices, a PMS report. PMCF is the clinical evidence part of this system.

In vitro diagnostics (IVD): PMPF

Under the In Vitro Diagnostic Regulation (IVDR), manufacturers must carry out post-market performance follow-up (PMPF), set out in IVDR Annex XIII Part B. PMPF tracks whether a test continues to perform as intended once it is used across real-world laboratories and sites. This includes diagnostic sensitivity and specificity, cross-reactivity, and false-positive and false-negative rates. Manufacturers must also show that performance stays consistent across different operators, analytical instruments, sample types and patient populations.

Software as a medical device (SaMD): drift monitoring

Software as a medical device (SaMD) follows the same PMCF requirements as other devices, or PMPF if the software is an IVD. For digital therapeutics, diagnostic imaging software and clinical decision support that uses artificial intelligence (AI), post-market evaluation focuses on:

  • Post-market drift monitoring: The main concern is whether model accuracy degrades over time as clinical practice, patient demographics or input data change. In the US, the FDA's Predetermined Change Control Plan (PCCP) guidance allows manufacturers to agree planned model updates in advance.
  • Real-world performance: Tracking user interface errors, clinician override rates and workload within Electronic Health Record (EHR) workflows.

Want to see how post-market studies fit with the earlier exploratory and confirmatory stages? Explore our complete guide to the phases of clinical trials.

Real-world examples of Phase 4 and PMCF studies

Post-market studies have shaped how some of the world's most widely used drugs and devices are used, and in some cases led to their withdrawal. Examples include:

Versius surgical robot registry (CMR Surgical)

CMR Surgical collects real-world data on procedures performed with its Versius surgical robot through a clinical registry built on Ledidi. Participating hospitals enter structured data on patients, procedures and outcomes into standardised forms. This produces a consistent, complete dataset across sites, which supports CMR's post-market evidence and gives surgeons data they can publish. One participating centre has already used its registry data in a peer-reviewed single-centre study of its Versius experience. This shows how a well-run post-market registry can generate evidence for clinicians and manufacturers alike. Read the CMR Surgical customer story.

Rofecoxib (Vioxx)

A long-term trial run after approval found an increased risk of heart attack and stroke in patients taking the painkiller. The manufacturer withdrew the drug worldwide in 2004.

Cardiovascular outcome trials for diabetes drugs

Since 2008, the FDA has expected new type 2 diabetes drugs to show they do not increase cardiovascular risk, often through large post-approval trials. Some of these trials went further. The EMPA-REG OUTCOME trial showed that empagliflozin reduced cardiovascular death, leading to a new approved indication.

Metal-on-metal hip implants

Data from the National Joint Registry for England and Wales showed higher than expected revision rates for certain metal-on-metal hip implants. This contributed to a worldwide recall of one implant system in 2010, and led to closer monitoring of patients with these devices.

Transcatheter aortic valve implantation (TAVI) registries

In the US, the national TVT Registry collects data on every commercial TAVI procedure. Regulators have used this registry data to support post-approval studies and expanded indications, showing how a well-run registry can generate evidence that benefits both patients and manufacturers.

Overcoming the biggest challenges in post-market studies

In both pharma Phase 4 and MedTech PMCF, a few challenges need to be addressed to get valuable data.

Long-term patient retention and loss to follow-up

Keeping patients in a study over time is essential. Updated patient data spanning 5, 10 or even 15 years, across clinics, gives a clear picture of the effects of a drug or device. But some patients will inevitably move, change hospitals or stop attending follow-up visits. High loss to follow-up weakens the evidence, and for medical devices it can lead notified bodies to judge the PMCF data insufficient. Remote follow-up, such as electronic patient-reported outcomes collected between visits, helps keep patients engaged and data complete.

Site fatigue

It is not only patients who need to stay engaged. Doctors and research nurses balance busy clinical workloads with time-consuming eCRF data entry. When clinical trial software or registry platforms require manual double data entry or complicated routines, investigator participation drops considerably. For that reason, no-code, streamlined eCRFs are a proven way to maintain high-quality post-market data entry over many years.

Data quality and heterogeneity

Harmonising data collected from multiple hospital EHR systems is a significant technical challenge. Every hospital records data differently, which makes it hard to validate and compare. A centralised clinical data management system with standardised forms and built-in validation checks keeps post-market data complete and consistent, and makes it far easier to produce the analyses needed for regulatory reports such as the Periodic Safety Update Report (PSUR).

Regulatory scrutiny

Notified bodies under the EU MDR, and FDA inspectors, expect post-market data to be collected in a controlled, audit-ready way, including in observational registries.

Manufacturers sometimes assume post-market data is held to a lower standard, but the same data integrity principles apply as in pre-market studies. PMCF studies must also follow ISO 14155:2020. In practice, this means complete audit trails, secure role-based access controls and electronic signatures that meet FDA 21 CFR Part 11, alongside data protection under the EU General Data Protection Regulation (GDPR).

How Ledidi supports Phase 4 trials and MedTech PMCF registries

Medical device and diagnostic manufacturers face an evolving regulatory landscape under the EU MDR, IVDR and FDA requirements. Post-market evidence often has to be collected across many sites over many years, and too often it ends up spread across disconnected tools. Ledidi supports a full evidence lifecycle approach by bringing electronic data capture (EDC), clinical data management and registries together on one audit-ready cloud platform. Customers can run every stage of their evidence programme in one place, from pivotal studies to Phase 4 trials, PMCF studies and long-term registries, with study teams and clinical sites using the same platform, interface and training throughout.

  • Streamlined multi-centre collaboration: Hospital teams, principal investigators and sponsors work in the same secure environment, with real-time analytics.
  • Audit-ready compliance: Ledidi Trials has been independently audited and confirmed audit-ready against FDA 21 CFR Part 11, ICH GCP E6 (R3) and ISPE GAMP 5, with data handled in line with GDPR. This helps your PMCF evidence stand up to notified body review.
  • Regulatory expertise through partners: For PMCF in particular, Ledidi has partnered with Mantra Systems, a regulatory consultancy where clinicians and regulatory specialists work in the same team. Mantra designs the PMCF strategy, protocol and questionnaires, while Ledidi handles enrolment, follow-up, monitoring, audit trail and export. Read about the partnership.

Whether you are moving from a pivotal trial into a multi-year PMCF registry, or setting up an international Phase 4 PASS, that means faster study start-up, direct ownership of your data and a platform built to stay inspection-ready throughout the commercial lifecycle.

Read more about clinical trial phases

Frequently asked questions

Is a Phase 4 clinical trial mandatory?

In many cases, yes. Regulators such as the FDA and EMA often grant marketing authorisation on the condition that the sponsor carries out Phase 4 commitments, for example under accelerated approval pathways. In MedTech, the EU MDR requires manufacturers to plan and carry out PMCF for CE-marked devices, and any decision not to do so must be justified. In the US, the FDA can require post-approval studies as a condition of Premarket Approval (PMA), and can order postmarket surveillance studies under Section 522 of the Federal Food, Drug, and Cosmetic Act.

Can a drug or device be recalled based on Phase 4 results?

Yes. If Phase 4 surveillance or PMCF reveals serious safety risks, unacceptable complication rates or a negative benefit-risk ratio, regulators can require label warnings, restrict indications or order a market withdrawal.

How long does a Phase 4 study typically last?

Phase 4 studies typically run for several years and can stay active for as long as the therapy is commercially available, often following cohorts for 5 to 10 years or more.

Sources

More From Ledidi Academy